Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
As of close of business last night, Vir Biotechnology Inc’s stock clocked out at $5.66, down -0.70% from its previous closing price of $5.7. In other words, the price has decreased by -$0.70 from its previous closing price. On the day, 1.23 million shares were traded. VIR stock price reached its highest trading level at $5.72 during the session, while it also had its lowest trading level at $5.425.
Ratios:
To gain a deeper understanding of VIR’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.01 and its Current Ratio is at 7.01. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.10.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Evercore ISI on September 03, 2025, initiated with a Outperform rating and assigned the stock a target price of $12.
On August 27, 2025, BofA Securities Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $14.
JP Morgan Downgraded its Overweight to Neutral on January 29, 2024, whereas the target price for the stock was revised from $23 to $9.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Oct 01 ’25 when SATO VICKI L sold 22,000 shares for $5.84 per share. The transaction valued at 128,396 led to the insider holds 1,232,391 shares of the business.
VICKI LEE SATO bought 66,000 shares of VIR for $376,860 on Oct 01 ’25. On Sep 02 ’25, another insider, SATO VICKI L, who serves as the Director of the company, sold 22,000 shares for $4.99 each. As a result, the insider received 109,811 and left with 1,254,391 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VIR now has a Market Capitalization of 786267008 and an Enterprise Value of 282477984. For the stock, the TTM Price-to-Sale (P/S) ratio is 41.38 while its Price-to-Book (P/B) ratio in mrq is 0.83. Its current Enterprise Value per Revenue stands at 14.867 whereas that against EBITDA is -0.509.
Stock Price History:
The Beta on a monthly basis for VIR is 1.26, which has changed by -0.26873386 over the last 52 weeks, in comparison to a change of 0.16766965 over the same period for the S&P500. Over the past 52 weeks, VIR has reached a high of $14.45, while it has fallen to a 52-week low of $4.16. The 50-Day Moving Average of the stock is 13.03%, while the 200-Day Moving Average is calculated to be -12.45%.
Shares Statistics:
It appears that VIR traded 1.28M shares on average per day over the past three months and 1290290 shares per day over the past ten days. A total of 138.89M shares are outstanding, with a floating share count of 90.45M. Insiders hold about 34.89% of the company’s shares, while institutions hold 57.00% stake in the company. Shares short for VIR as of 1757894400 were 11852892 with a Short Ratio of 9.26, compared to 1755216000 on 11487884. Therefore, it implies a Short% of Shares Outstanding of 11852892 and a Short% of Float of 13.750000000000002.
Earnings Estimates
The market rating for Vir Biotechnology Inc (VIR) is a result of the insights provided by 7.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.71, with high estimates of -$0.59 and low estimates of -$0.85.
Analysts are recommending an EPS of between -$2.87 and -$3.84 for the fiscal current year, implying an average EPS of -$3.26. EPS for the following year is -$2.88, with 8.0 analysts recommending between -$2.4 and -$3.54.
Revenue Estimates
For the next quarter, 7 analysts are estimating revenue of $2.05M. There is a high estimate of $3.9M for the next quarter, whereas the lowest estimate is $500k.
A total of 9 analysts have provided revenue estimates for VIR’s current fiscal year. The highest revenue estimate was $37M, while the lowest revenue estimate was $4.7M, resulting in an average revenue estimate of $11.47M. In the same quarter a year ago, actual revenue was $74.2MBased on 9 analysts’ estimates, the company’s revenue will be $13.22M in the next fiscal year. The high estimate is $29.65M and the low estimate is $3M.
